Integrilin in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction.

M Mahmoudi; C Delhaye; K Wakabayashi; R Torguson; Z Xue; WO Suddath; LF Satler; KM Kent; AD Pichard; R Waksman

doi:10.1111/j.1540-8183.2011.00632.x

Back

Integrilin in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction.

Journal article

Peer reviewed

Integrilin in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction.

M Mahmoudi, C Delhaye, K Wakabayashi, R Torguson, Z Xue, WO Suddath, LF Satler, KM Kent, AD Pichard and R Waksman

J Interv Cardiol, Vol.24(4), pp.351-356

08/2011

DOI: https://doi.org/10.1111/j.1540-8183.2011.00632.x

Abstract

Aged

Angioplasty

Balloon

Coronary

Chemotherapy

Adjuvant

Cohort Studies

Female

Humans

Male

Middle Aged

Myocardial Infarction

Peptides

Platelet Aggregation Inhibitors

Registries

Retrospective Studies

Treatment Outcome

The adjunctive use of eptifibatide in patients undergoing primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI) remains controversial. We therefore set out to determine the safety and efficacy of eptifibatide in this population.

Metrics

20 Record Views

9 Times Cited - Web of Science

Details

Title: Integrilin in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction.
Creators: M Mahmoudi
C Delhaye
K Wakabayashi
R Torguson
Z Xue
WO Suddath
LF Satler
KM Kent
AD Pichard
R Waksman
Publication Details: J Interv Cardiol, Vol.24(4), pp.351-356
Date published: 08/2011
Date submitted: 17/05/2017
Identifiers: 99515215402346
Academic Unit: University of Surrey
Language: English
Resource Type: Journal article

Integrilin in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction.

Abstract

Metrics

Details

Usage Policy